Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(40.0%)
Phase 1
2(40.0%)
Phase 3
1(20.0%)
5Total
Phase 2(2)
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06107205Phase 1Completed

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

Role: lead

NCT07252440Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

Role: lead

NCT06757504Phase 2Recruiting

Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD

Role: lead

NCT06648304Phase 3Completed

Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke

Role: lead

NCT04370431Phase 1Completed

A Study of TTYP01 in Healthy Adult Subjects

Role: lead

All 5 trials loaded